Jazz Pharmaceuticals to acquire Actio Biosciences for $820M upfront

August 10, 2026 7:30 AM

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has agreed to acquire privately held Actio Biosciences, Inc. for $820 million upfront and up ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found